Mechanisms of action of intravenous immunoglobulins

Expert Review of Clinical Immunology

Volumn 6, Issue 3, 2010, Pages 425-434

  Baerenwaldt, Anne ^a   Biburger, Markus ^a   Nimmerjahn, Falk ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Fc receptors; Idiopathic thrombocytopenia purpura; Immunoglobulin G; Inflammation; IVIg; Macrophage; SignR1

Indexed keywords

ALPHA INTERFERON; CD16 ANTIGEN; FC RECEPTOR IIB; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G3; MONOCLONAL ANTIBODY; SIALIC ACID;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; DENDRITIC CELL; DRUG MECHANISM; EOSINOPHIL; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE COMPLEX NEPHRITIS; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; MACROPHAGE; MONOCYTE; MULTIPLE SCLEROSIS; NEUTROPHIL; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOGLOBULINS, INTRAVENOUS; MACROPHAGES; MICE; MONOCYTES; N-ACETYLNEURAMINIC ACID; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RATS; RECEPTORS, FC;

EID: 77952058848     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.9     Document Type: Review

References (94)

1. Nimmerjahn, F, Ravetch JV. Antiinflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 26, 513-533 (2008).
2. Negi VS, Elluru S, Siberil S et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J. Clin. Immunol. 27 (3), 233-245 (2007).
3. Toubi E, Etzioni A. Intravenous immunoglobulin in immunodeficiency states: state of the art. Clin. Rev. Allergy Immunol. 29 (3), 167-172 (2005).
4. Imbach P, Barandun S, d'Apuzzo V et al. High-dose intravenous γ globulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1 (8232), 1228-1231 (1981).
5. •• Together with reference [5], this was the first demonstration that intravenous immunoglobulin (IVIg) has therapeutic activity in autoimmune thrombocytopenia.
6. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous γ globulin. N. Engl. J. Med. 306 (21), 1254-1258 (1982).
7. Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intravenous IgG paradox. J. Exp. Med. 204 (1), 11-15 (2007).
8. Crow AR, Lazarus AH. The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know? Transfus. Med. Rev. 22 (2), 103-116 (2008).
9. Imbach P, Lazarus AH, Kuhne T. Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders. Vox. Sang. 98, 385-394 (2009).
10. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282 (5388), 490-493 (1998).
11. Altznauer F, von Gunten S, Spath P, Simon HU. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J. Allergy Clin. Immunol. 112 (6), 1185-1190 (2003).
12. von Gunten S, Schaub A, Vogel M et al. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 108 (13), 4255-4259 (2006).
13. von Gunten S, Vogel M, Schaub A et al. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J. Allergy Clin. Immunol. 119 (4), 1005-1011 (2007).
14. de Grandmont MJ, Racine C, Roy A, Lemieux R, Neron S. Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG. Blood 101 (8), 3065-3073 (2003).
15. Le Pottier L, Sapir T, Bendaoud B et al. Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann. NY Acad. Sci. 1110, 426-432 (2007).
16. + regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111 (2), 715-722 (2008).
17. Kessel A, Ammuri H, Peri R et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J. Immunol. 179 (8), 5571-5575 (2007).
18. De Groot AS, Moise L, McMurry JA et al. Activation of natural regulatory T cells by IgG Fc-derived peptide 'Tregitopes'. Blood 112 (8), 3303-3311 (2008).
19. Bayry J, Lacroix-Desmazes S, Carbonneil C et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101 (2), 758-765 (2003).
20. Bayry J, Lacroix-Desmazes S, Delignat S et al. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-α present in serum from patients with systemic lupus erythematosus. Arthritis Rheum. 48 (12), 3497-3502 (2003).
21. Tha-In T, Metselaar HJ, Tilanus HW et al. Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells. Blood 110 (9), 3253-3262 (2007).
22. Basta M. Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition. Mol. Immunol. 45 (16), 4073-4079 (2008).
23. Basta M, Van Goor F, Luccioli S et al F (ab) '2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat. Med. 9 (4), 431-438 (2003).
24. Carroll MC. The complement system in regulation of adaptive immunity. Nat. Immunol. 5 (10), 981-986 (2004).
25. Baumann U, Kohl J, Tschernig T et al. A codominant role of FcγRI/III and C5aR in the reverse Arthus reaction. J. Immunol 164 (2), 1065-1070 (2000).
26. Kumar V, Ali SR, Konrad S et al. Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J. Clin. Invest. 116 (2), 512-520 (2006).
27. Schmidt RE, Gessner JE. Fc receptors and their interaction with complement in autoimmunity. Immunol. Lett. 100 (1), 56-67 (2005).
28. Tackenberg B, Jelcic I, Baerenwaldt A et al Impaired inhibitory Fc γ receptor IIB expression on B cells in chronic infammatory demyelinating polyneuropathy. Proc. Natl Acad. Sci. USA 106 (12), 4788-4792 (2009).
29. • First demonstration that IVIg modulates Fcγ receptor IIB (FcγRIIB) expression in humans.
30. Nikolova KA, Tchorbanov AI, Djoumerska-Alexieva IK, Nikolova M, Vassilev TL. Intravenous immunoglobulin up-regulates the expression of the inhibitory Fcγ IIB receptor on B cells. Immunol. Cell Biol. 87 (7), 529-533 (2009).
31. Bruhns P, Samuelsson A, Pollard JW, Ravetch JV. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18 (4), 573-581 (2003).
32. Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch JV. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J. Exp. Med. 203 (3), 789-797 (2006).
33. Kaneko Y, Nimmerjahn F, Ravetch JV Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (5787), 670-673 (2006).
34. •• Shows that IgG glycovariants rich in sialic acid are crucial for the anti-inflammatory activity of IVIg.
35. Samuelsson A, Towers TL, Ravetch JV Anti-infammatory activity of IVIg mediated through the inhibitory Fc receptor. Science 291 (5503), 484-486 (2001).
36. Bolland S, Ravetch JV. Inhibitory pathways triggered by ITIM-containing receptors. Adv. Immunol. 72, 149-177 (1999).
37. Ono M, Okada H, Bolland S et al Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling. Cell 90 (2), 293-301 (1997).
38. Pearse RN, Kawabe T, Bolland S et al SHIP recruitment attenuates Fc γ IIB-induced B cell apoptosis. Immunity 10 (6), 753-760 (1999).
39. Xiang Z, Cutler AJ, Brownlie RJ et al FcγRIIb controls bone marrow plasma cell persistence and apoptosis. Nat. Immunol 8 (4), 419-429 (2007).
40. • Together with [35], this study demonstrates the important role of the inhibitory FcγRIIB for plasma cell homeostasis.
41. Mackay M, Stanevsky A, Wang T et al Selective dysregulation of the Fcg IIB receptor on memory B cells in SLE. J. Exp. Med. 203 (9), 2157-2164 (2006).
42. Baerenwaldt A, Nimmerjahn F. Immune regulation: Fc γ RIIB - regulating the balance between protective and autoreactive immune responses. Immunol Cell Biol. 86 (6), 482-484 (2008).
43. Brownlie RJ, Lawlor KE, Niederer HA et al. Distinct cell-specific control of autoimmunity and infection by FcγRIIb. J. Exp. Med. 205 (4), 883-895 (2008).
44. McGaha TL, Sorrentino B, Ravetch JV. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 307 (5709), 590-593 (2005).
45. Takai T Roles of Fc receptors in autoimmunity Nat. Rev. Immunol. 2 (8), 580-592 (2002).
46. Nimmerjahn F, Ravetch JV. Fcg receptors as regulators of immune responses. Nat. Rev. Immunol. 8 (1), 34-47 (2008).
47. Debre M, Bonnet MC, Fridman WH et al Infusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342 (8877), 945-949 (1993). •• This was the first demonstration that the antibody Fc fragment has anti-inflammatory activity in humans.
48. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7 (9), 715-725 (2007).
49. Ravetch JV, Nimmerjahn F. Fc receptors. In: Fundamental Immunology. Paul WE (Ed.). Lippincott-Raven, PA, USA, 684-705 (2009).
50. 111indium-labelled human platelets. Br. J. Haematol. 44 (2), 269-280 (1980).
51. Nimmerjahn F, Ravetch JV. Fcγ receptors: old friends and new family members. Immunity 24 (1), 19-28 (2006).
52. Hogarth PM. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr. Opin. Immunol. 14 (6), 798-802 (2002).
53. Clarkson SB, Kimberly RP, Valinsky JE et al. Blockade of clearance of immune complexes by an anti-Fc γ receptor monoclonal antibody. J. Exp. Med. 164 (2), 474-489 (1986). • Demonstrates that blocking activating Fcγ receptors in humans has therapeutic activity in idiopathic thrombocytopenia purpura.
54. Sylvestre D, Clynes R, Ma M et al. Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. J. Exp. Med. 184 (6), 2385-2392 (1996).
55. Ravetch JV, Clynes RA. Divergent roles for Fc receptors and complement in vivo. Annu. Rev. Immunol. 16, 421-432 (1998).
56. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99 (3), 754-758 (2002).
57. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J. Clin. Oncol. 22 (23), 4717-4724 (2004).
58. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21 (21), 3940-3947 (2003).
59. Park-Min KH, Serbina NV, Yang W et al. FcγRIII-dependent inhibition of interferon-γ responses mediates suppressive effects of intravenous immune globulin. Immunity 26 (1), 67-78 (2007).
60. Nimmerjahn F, Ravetch J V. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310 (5753), 1510-1512 (2005).
61. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcγRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23 (1), 41-51 (2005).
62. Fossati-Jimack L, Ioan-Facsinay A, Reininger L et al. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcγ receptor III. J. Exp. Med. 191 (8), 1293-1302 (2000).
63. Meyer D, Schiller C, Westermann J et al. FcγRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia. Blood 92 (11), 3997-4002 (1998).
64. Hazenbos WL, Gessner JE, Hofhuis FM et al. Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc γ RIII (CD16) deficient mice. Immunity 5 (2), 181-188 (1996).
65. Syed SN, Konrad S, Wiege K et al. Both FcγRIV and FcγRIII are essential receptors mediating type II and type III autoimmune responses via FcRγ-LAT-dependent generation of C5a. Eur. J. Immunol. 39 (12), 3269-3585 (2009).
66. Giorgini A, Brown HJ, Lock HR et al. Fcγ RIII and Fc γ RIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies. J. Immunol. 181 (12), 8745-8752 (2008).
67. Baudino L, Nimmerjahn F, da Silveira SA et al. Differential contribution of three activating IgG Fc receptors (FcγRI, FcγRIII, and FcγRIV) to IgG2a-and IgG2b-induced autoimmune hemolytic anemia in mice. J. Immunol. 180 (3), 1948-1953 (2008).
68. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fc γ receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203 (3), 743-753 (2006).
69. Daeron M, Lesourne R. Negative signaling in Fc receptor complexes. Adv. Immunol. 89, 39-86 (2006).
70. Hansen RJ, Balthasar JP. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 100 (6), 2087-2093 (2002).
71. Hansen RJ, Balthasar JP. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb. Haemost. 88 (6), 898-899 (2002).
72. Masson PL. Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg. J. Autoimmun. 6 (6), 683-689 (1993).
73. Li N, Zhao M, Hilario-Vargas J et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J. Clin. Invest. 115 (12), 3440-3450 (2005).
74. Akilesh S, Petkova S, Sproule TJ et al. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J. Clin. Invest. 113 (9), 1328-1333 (2004).
75. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25, 21-50 (2007).
76. Shields RL, Namenuk AK, Hong K et al. High resolution mapping of the binding site on human IgG1 for Fc γ RI, Fc γ RII, Fc γ RIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J. Biol. Chem. 276 (9), 6591-6604 (2001).
77. Bruhns P, Iannascoli B, England P et al. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 113 (16), 3716-3725 (2009).
78. Bussel JB, Graziano JN, Kimberly R P, Pahwa S, Aledort LM. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood 77 (9), 1884-1893 (1991).
79. Siragam V, Brinc D, Crow AR et al. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J. Clin. Invest. 115 (1), 155-160 (2005).
80. Song S, Crow AR, Freedman J, Lazarus AH. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Blood 101 (9), 3708-3713 (2003).
81. Teeling JL, Jansen-Hendriks T, Kuijpers TW et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 98 (4), 1095-1099 (2001).
82. Dolman C, Thorpe SJ, Thorpe R. Enhanced efficacy of anti-D immunoglobulin for treating ITP is not explained by higher immunoglobulin polymer content. Biologicals 29 (2), 75-79 (2001).
83. Spycher M, Matozan K, Minnig K et al. In vitro comparison of the complementscavenging capacity of different intravenous immunoglobulin preparations. Vox. Sang. 97 (4), 348-354 (2009).
84. Siragam V, Crow AR, Brinc D et al. Intravenous immunoglobulin ameliorates ITP via activating Fc γ receptors on dendritic cells. Nat. Med. 12 (6), 688-692 (2006). • Shows that dendritic cells may be involved in IVIg activity.
85. Crow AR, Brinc D, Lazarus AH. New insight into the mechanism of action of IVIg: the role of dendritic cells. J. Thromb. Haemost. 7 (Suppl. 1), 245-248 (2009).
86. Crow AR, Song S, Freedman J et al. IVIg-mediated amelioration of murine ITP via FcγRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 102 (2), 558-560 (2003).
87. Crow AR, Song S, Semple JW, Freedman J, Lazarus AH. A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg? Blood 109 (1), 155-158 (2007). • Excludes the involvement of several cytokines in IVIg activity.
88. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identifcation of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl Acad. Sci. USA 105 (50), 19571-19578 (2008). • First description of a novel antiinfammatory pathway essential for the therapeutic activity of IVIg.
89. Anthony RM, Nimmerjahn F, Ashline DJ et al. Recapitulation of IVIG antiinflammatory activity with a recombinant IgG Fc. Science 320 (5874), 373-376 (2008). • First study to generate a recombinant IVIg in tissue culture.
90. Stadlmann J, Weber A, Pabst M et al. A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics 9 (17), 4143-4153 (2009).
91. Parekh RB, Dwek RA, Sutton BJ et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316 (6027), 452-457 (1985). • Shows that autoimmune patients have a skewed serum glycosylation pattern.
92. Rademacher TW, Williams P, Dwek RA. Agalactosyl glycoforms of IgG autoantibodies are pathogenic. Proc. Natl Acad. Sci. USA 91 (13), 6123-6127 (1994).
93. Nimmerjahn F, Anthony RM, Ravetch JV. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity Proc. Natl Acad. Sci. USA 104 (20), 8433-8437 (2007).
94. Malhotra R, Wormald MR, Rudd PM et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannosebinding protein. Nat. Med. 1 (3), 237-243 (1995).